CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

被引：0
|
作者：
H S Wasan
G M Springett
C Chodkiewicz
R Wong
J Maurel
C Barone
B Rosbrook
A D Ricart
S Kim
J-P Spano
机构：
[1] Hammersmith Hospital,Department of Cancer Medicine
[2] H. Lee Moffitt Cancer Center and Research Institute,undefined
[3] Cancer Care Manitoba,undefined
[4] St. Boniface General Hospital,undefined
[5] Hospital Clinic de Barcelona,undefined
[6] CIBEREHD,undefined
[7] Catholic University Sacro Cuore,undefined
[8] Pfizer Oncology,undefined
[9] Science Center Drive,undefined
[10] Hôpital de la Pitié Salpêtrière,undefined
[11] 47–83 Boulevard de l'Hôpital,undefined
[12] 75651,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
advanced pancreatic cancer; CA 19-9; biomarkers; axitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1162 / 1167
页数：5
相关论文
共 50 条
  • [1] CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
    Wasan, H. S.
    Springett, G. M.
    Chodkiewicz, C.
    Wong, R.
    Maurel, J.
    Barone, C.
    Rosbrook, B.
    Ricart, A. D.
    Kim, S.
    Spano, J-P
    BRITISH JOURNAL OF CANCER, 2009, 101 (07) : 1162 - 1167
  • [2] Prognostic and therapeutic significance of CA 19-9 as biomarker in patients with advanced pancreatic cancer receiving gemcitabine (GEM) plus axitinib (AG-013736) or GEM alone
    Maurel, J.
    Chodkiewicz, C.
    Spano, J.
    Wong, R.
    Wasan, H.
    Barone, C.
    Rosbrook, B.
    Ricart, A.
    Kim, S.
    Rixe, O.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [3] Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
    Spano, Jean-Philippe
    Chodkiewicz, Catherine
    Maurel, Joan
    Wong, Ralph
    Wasan, Harpreet
    Barone, Carlo
    Letourneau, Richard
    Bajetta, Emilio
    Pithavala, Yazdi
    Bycott, Paul
    Trask, Peter
    Liau, Katherine
    Ricart, Alejandro D.
    Kim, Sinil
    Rixe, Olivier
    LANCET, 2008, 371 (9630): : 2101 - 2108
  • [4] CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer
    Nakai, Yousuke
    Kawabe, Takao
    Isayama, Hiroyuki
    Sasaki, Takashi
    Yagioka, Hiroshi
    Yashima, Yoko
    Kogure, Hirofumi
    Arizumi, Toshihiko
    Togawa, Osamu
    Ito, Yukiko
    Matsubara, Saburo
    Hirano, Kenji
    Sasahira, Naoki
    Tsujino, Takeshi
    Tada, Minoru
    Omata, Masao
    ONCOLOGY, 2008, 75 (1-2) : 120 - 126
  • [5] Prognostic value of CA 19-9 in patients with pancreatic cancer treated with Gemcitabine
    Halm, U
    Schuhmann, T
    Keim, V
    Moessner, J
    GASTROENTEROLOGY, 1999, 116 (04) : A1129 - A1129
  • [6] Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
    Everardo D. Saad
    Marcel C. Machado
    Dalia Wajsbrot
    Roberto Abramoff
    Paulo M. Hoff
    Jacques Tabacof
    Artur Katz
    Sergio D. Simon
    René C. Gansl
    International Journal of Gastrointestinal Cancer, 2002, 32 : 35 - 41
  • [7] Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
    Saad, ED
    Machado, MC
    Wajsbrot, D
    Abramoff, R
    Hoff, PM
    Tabacof, J
    Katz, A
    Simon, SD
    Gansl, RC
    JOURNAL OF GASTROINTESTINAL CANCER, 2002, 32 (01) : 35 - 41
  • [8] Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    Halm U.
    Schumann T.
    Schiefke I.
    Witzigmann H.
    Mössner J.
    Keim V.
    British Journal of Cancer, 2000, 82 (5) : 1013 - 1016
  • [9] Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    Halm, U
    Schumann, T
    Schiefke, I
    Witzigmann, H
    Mössner, J
    Keim, V
    BRITISH JOURNAL OF CANCER, 2000, 82 (05) : 1013 - 1016
  • [10] Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer
    Eileen M O'Reilly
    Ghassan K Abou-Alfa
    Nature Clinical Practice Oncology, 2008, 5 : 312 - 313
12345